Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.
The FDA places a clinical hold on Neumora's (NMRA) phase I study evaluating NMRA-266 for some types of neuropsychiatric disorders. Shares of the company fall on the news.
Neumora said Monday the FDA put its schizophrenia drug on hold after rabbits experienced convulsions, and the biotech stock plunged.